АИАнна Александровна Иванова

Анна Александровна Иванова

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Анна Александровна Иванова has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Potential of Dual-Phase 68Ga-FAPI PET/CT in the Differential Diagnosis of Focal Liver Lesions

    by A. A. Ivanova, D. V. Ryzhkova, K. E. Sanarova, I. O. Rutkin, A. A. Stanzhevskii, A. A. Maystrenko, D. N. Maystrenko

    Introduction. Recent studies have confirmed the effectiveness of positron emission tomography combined with computed tomography (PET/CT) using radiolabeled ligands of fibroblast activation protein inhibitors (FAPI) for the visualization of malignant lesions (ML) and benign lesions (BL). The objective was to evaluate the diagnostic utility of dual-phase PET/CT with 68 Ga-FAPI-04 in patients with focal liver lesions of varying etiology. Methods and materials. The study enrolled 62 patients with focal liver lesions of diverse etiologies for the purpose of differential diagnosis (20/62 patients) and pretreatment staging (42/62 patients). 68 Ga-FAPI-04 PET/CT imaging was performed in two phases: Phase I (PET/CT 20 ) – imaging began 20 minutes after administration of 68 Ga-FAPI-04 (limited to the abdominal region); Phase II (PET/CT 60 ) – 60 minutes after injection, performed as a «Whole-body» scan. Image analysis included visual assessment and calculation of the maximum standardized uptake value (SUVmax) over the lesion areas. Results. Comprehensive clinical and imaging evaluation identified a total of 128 focal liver lesions. At the early-phase PET/CT scan (PET/CT 20 ), increased 68 Ga-FAPI-04 uptake was observed in 109 of 128 lesions (85.2 %): 18 of 25 BL and 91 of 103 ML. A comparable uptake pattern was seen on the delayed-phase scan (PET/CT 60 ): 18 of 25 BL and 93 of 103 ML. Visual and quantitative analyses of dual-phase 68 Ga-FAPI-04 PET/CT demonstrated no significant differences in sensitivity, specificity, and diagnostic accuracy between phase I and phase II for the differential diagnosis of focal liver lesions. Visual assessment yielded values of 88.3 %, 28 %, 76.6 % for phase I versus 90.3 %, 28 %, 78.1 % for phase II. Quantitative analysis of 68 Ga-FAPI-04 uptake intensity in hepatic lesions showed corresponding values of 73.8 %, 64 %, 74.2 % for phase I and 68 %, 72 %, 71.6 % for phase II. Conclusion: Elevated 68 Ga-FAPI-04 uptake was observed in the majority of hepatic lesions during both early and delayed imaging phases, irrespective of lesion etiology. Given the absence of significant diagnostic gain between time points, dual-phase PET/CT acquisition appears unnecessary for differentiating the etiology of liver lesions. Quantitative assessment using SUVmax values contributes to improved specificity of 68 Ga-FAPI-04 PET/CT in identifying malignant hepatic involvement.

  • Imaging of active bioprosthetic valve degeneration using 68GA-FAPI-04 PET/CT: a pilot study of pathophysiological mechanisms and diagnostic value

    by A. D. Majstrenko, A. A. Ivanova, A. A. Stanzhevskij, V. E. Uspenskij, D. V. Ryzhkova, A. A. Popova, E. B. Ioffe, V. V. Zjuleva, A. Ju. Kneev, M. Gordeev

    Structural valve deterioration (SVD) remains the major limitation of bioprosthetic heart valves (BHV). Current imaging modalities (Echocardiography, CT) detect SVD at late stages of irreversible damage. This study aimed to evaluate the potential of 68Ga-FAPI-04 PET/CT, a marker of fibroblast activation, for the early visualization of active BHV remodeling and to assess its correlation with hemodynamic dysfunction. We performed a cross-sectional analysis of 30 patients with implanted aortic BHVs. All patients underwent transthoracic echocardiography and 68Ga-FAPI-04 PET/CT. Tracer uptake was quantified using the Differential Uptake Ratio (DUR). Statistical analysis included Spearman’s rank correlation, partial correlation to adjust for confounders, bootstrap analysis (5,000 resamples) for verification, and ROC analysis to determine diagnostic accuracy. DUR demonstrated a statistically significant positive correlation with peak transprosthetic pressure gradient (rs = 0.404, p = 0.027). Notably, an inverse correlation was observed between DUR and Left Ventricular Ejection Fraction (rs =–0.411, p = 0.024). Partial correlation analysis confirmed that the association between DUR and prosthetic gradients remained significant (rpartial = 0.385, p = 0.036) even after adjusting for LVEF, indicating that tracer uptake reflects intrinsic valve pathology rather than systemic heart failure. The intensity of FAP-targeted signal did not correlate with patient age or time since implantation (p >0.05). Specificity analysis showed no association between DUR and comorbidities (diabetes, renal failure) or gender. ROC analysis yielded an AUC of 0.682 (95 % CI: 0.478–0.887) for detecting severe dysfunction, with an optimal cut-off value of DUR > 2.35. The method visualizes active fibroblast-mediated remodeling in bioprosthetic valves, which correlates with hemodynamic deterioration but occurs independently of chronologic valve age and provides a specific molecular signal of SVD that is distinct from systemic factors or cardiac performance artifacts.

  • Open Access

    Comparative Performance of 68Ga-FAPI-04 and ¹8F-FDG PET/CT for Detection of Malignant Tumors and Metastases

    by Анна Александровна Иванова, Дарья Викторовна Рыжкова, Андрей Алексеевич Станжевский, Ксения Евгеньевна Санарова, Дарья Андреевна Важенина, Алексей Дмитриевич Майстренко, Максим Владимирович Артемов, Дмитрий Николаевич Майстренко

    Введение. Данные о диагностическом преимуществе радиофармацевтического лекарственного препарата (РФЛП) на основе ингибитора белка активации фибробластов (68Ga-ФАПИ-04) над хорошо себя зарекомендовавшим в онкологии туморотропным РФЛП 18F-ФДГ (18F-фтордезоксиглюкозой) изучены недостаточно на небольших когортах пациентов, а доступные литературные сведения противоречивы. Цель. — Выполнить сравнительный анализ информативности позитронно-эмиссионной томографии, совмещенной с рентгеновской компьютерной томографией (ПЭТ/КТ), с 68Ga-ФАПИ-04 и 18F-ФДГ в идентификации злокачественных опухолей и их метастазов. Материалы и методы. В исследование включено 66 пациентов: 30 мужчин и 36 женщин, медиана возраста — 54 года (22-83 года), с гистологически верифицированными злокачественными новообразованиями (ЗНО) различных локализаций. ПЭТ/КТ с двумя РФЛП — 68Ga-ФАПИ-04 и 18F-ФДГ, выполнена до начала противоопухолевого лечения 34 (52 %) из 66 пациентов с целью стадирования опухолевого процесса, 32 (48 %) пациентам ПЭТ/КТ проводили с целью диагностики местного рецидива опухоли и метастазов. Интервал между исследованиями не превышал семь дней. Результаты. Чувствительность 68Ga-ФАПИ-04 в выявлении как первичной опухоли, так и оценки распространенности заболевания была достоверно выше чувствительности 18F-ФДГ и составила 93,9 против 77,3 %, p = 0,006. У 33 (97,1 %) из 34 пациентов с первичными новообразованиями была выявлена патологическая гиперфиксация 68Ga-ФАПИ-04 в опухоли, при ПЭТ/КТ с 18F-ФДГ факт наличия первичной опухоли был установлен только в 24 случаях (70,6 %). Общий объем гиперэкспрессии белка активации фибробластов (fibroblast activation protein, FAP) был достоверно выше при исследовании с 68Ga-ФАПИ-04, чем общий метаболический объем опухоли (total metabolic tumor volume, TMTV) при ПЭТ/КТ с 18F-ФДГ: 34,7 (11;75,66) против 11,07 (0; 49,5) (p = 0,021). Чувствительность в выявлении костных метастазов и метастазов в печень была выше при исследовании с 68Ga-ФАПИ-04 по сравнению c 18F-ФДГ (92,6 против 85,2 %, p = 0,046; и 90,2 против 68,3 % соответственно, p = 0,014). Чувствительность ПЭТ/КТ в выявлении метастазов в лимфатические узлы была выше для 68Ga-ФАПИ-04 (81,1 против 73 % соответственно, p = 0,044), но зависела от размеров лимфатических узлов. Выводы. ПЭТ/КТ с 68Ga-ФАПИ-04 превосходит по чувствительности ПЭТ/КТ 18F-ФДГ в идентификации первичной и рецидивной опухоли, а также метастатической диссеминации и опухолевой нагрузки.


  • Open Access

    Initial Clinical Experience with Established and Novel Radiopharmaceuticals for Radionuclide Therapy

    by Андрей Алексеевич Станжевский, Олег Евгеньевич Молчанов, Дмитрий Николаевич Майстренко, Дарья Андреевна Важенина, Мария Викторовна Одинцова, Анна Александровна Иванова, Лариса Александровна Чипига, Валерия Борисовна Номоконова

    Введение. Основная идея персонализированной ядерной медицины заключается в разработке тераностических пар, позволяющих одновременно проводить диагностику состояния пациента и осуществлять целенаправленное лечебное воздействие. Цель. Оценка эффективности пептидной рецепторной радионуклидной терапии (ПРРТ) у пациентов с метастатическим кастрационно-резистентным раком предстательной железы (мККРПЖ), нейроэндокринными опухолями (НЭО), а также генерализованными опухолями поджелудочной железы; определение частоты и степени выраженности нефротоксичности на фоне проводимой терапии; изучение возможностей радиофармацевтичекого лекарственного препарата (РФЛП) «Нанолют, Lu177» для персонализированного подхода к лечению пациентов с генерализованными опухолями почки и мочевого пузыря. Материалы и методы. Проведено 130 курсов ПРРТ 33 пациентам с мККРПЖ и 18 пациентам НЭО, а также 10 курсов ПРРТ четырем пациентам с генерализованными прогрессирующими опухолями поджелудочной железы и рецептор-негативной НЭО. Оценка эффективности лечения проводилась по данным ПЭТ/КТ с РФЛП 68Ga-ПСМА, 68Ga-ДОТА-ТАТЕ или 68Ga-ФАПИ. Интервал между сканированиями составлял 12-14 нед. в процессе терапии и через 3–6–12 мес. после ее завершения. Оценка патологических очагов производилась по шкале RECIST 1.1 по КТ-составляющей метода и по факту отсутствия\появления новых очагов гиперфиксации РФЛП для ПЭТ-части. Радиофармацевтический препарат 177Lu «Нанолют, Lu177» вводился в диапазоне доз от 500–700 МБк до 2,9–3,0 ГБк с применением у части пациентов нефропротективного протокола (альбумин + лазикс с последующей компенсацией утраченного объема физиологическим раствором и электролитами). Результаты. По результатам ПЭТ/КТ, частота объективных ответов у пациентов со злокачественными новообразованиями предстательной железы составила 24,2 % (восемь пациентов), тогда как у пациентов с НЭО этот показатель достиг 44,4 % (восемь пациентов). У 18 % (шесть человек) пациентов с мККРПЖ пептидная рецепторная терапия оказалась неэффективной. Продолжительность жизни до прогрессирования у пациентов с мККРПЖ составила от 2 до 17 мес., в среднем — 10,0 ± 4,8 мес.; продолжительность наблюдения за пациентами с НЭО составляет от 4 до 30 мес., в среднем — 19,2 ± 10,0 мес. При оценке распределения РФЛП «Нанолют, Lu177» выявлена патологическая гиперфиксация РФЛП в опухолевой ткани, которая зависела от введенной активности, размеров и локализации очагов. Повреждения почечной паренхимы у пациентов, проходивших терапию с использованием всех РФП, установлено не было. Заключение. ПРРТ пациентов с мККРПЖ и НЭО продемонстрировала высокую эффективность, сопоставимую с литературными данными относительно продолжительности жизни без прогрессирования, частоты объективных ответов и возникновения нежелательных эффектов. «Нанолют, Lu177» представляет собой перспективный РФЛП для терапевтического воздействия на генерализованные опухоли почки и мочевого пузыря.

  • Open Access

    Baseline volumetric parameters of PET/CT 18F-FDG and international prognostic index at patients with diffuse B-cell large cell lymphoma

    by Yu. N. Vinogradova, M. S. Tlostanova, A. A. Ivanova, M. I. Zelyanina, N. V. Ilyin

    INTRODUCTION: Metabolic tumor volume (MTV) and Tumor lesion glycolysis (TLG) are used in 18F-fluorodeoxyglucose Positron-Emission Tomography combined with Computed Tomography (18F-FDG PET/CT) as biometric markers in whole tumor. International prognostic index (IPI) has been used during 30 years at patients with diffuse B-cell large cell lymphoma (DLBCL) for prognosis, use MTV and TLG was unknown. Our aims were to determinate the best statistical relationship between MTV, TLG and IPI in patients with DLBCL.OBJECTIVE: Complex study of baseline volumetric parameters PET/CT with 18F-FDG at patients with DLBCL and assessment of their correlation with prognostic groups.MATERIALS AND METHODS: Baseline 18F-FDG PET/CT performed in 31 primary patients with DLBCL and evaluated SUVmax, MTV, TMTV, TLG, TTLG at different involved anatomic zones; correlation between PET biomarkers and prognostic groups of patients.Statistics: The research materials were subjected to statistical processing using the methods of correlation and regression analyses.RESULTS: SUVmax mean level didn’t discerned at patients of low and high-risk groups, but TMTV has been less in favorable prognostic, than in unfavorable groups (152±3.0 sm3 vs 890±178 sm3 p3 vs 7640±2067 g/ml×sm3 , pDISCUSSION: The 30-year experience of using IPI in assessing the prognosis of patients with DLBCL has shown its insufficient effectiveness in many clinical situations, and the R-IPI prognostic model has been tested on a smaller number of patients and can only be considered additionally. We studied in detail the initial volumetric parameters of patients with DLBCL in different regions of the lesion and their relationship with the level of prognosis according to the IPI criteria. Our data on large values of volumetric parameters in the infradiaphragmatic areas and bones may be related to the worse prognosis in patients with these localizations. Further broader studies of the initial volumetric biomarkers of PET in DLBCL patients will contribute to the development of approximate boundaries of specific volumetric parameters for different tumor localizations.CONCLUSION: The results obtained showed that the baseline volumetric parameters PET/CT at patients with DLBCL have significant connection with prognostic groups of patients and can be additional factors to influence of tactics of therapy.

  • Open Access

    68Ga-FAPI-04: the first experience of clinical application in Russia

    by A. A. Ivanova, A. A. Stanzhevskii, D. N. Maystrenko, S. V. Shatik, D. S. Sysoev, Yu. O. Antuganova, M. A. Nadporojskii, D. O. Antuganov

    INTRODUCTION: According to the literature, 68Ga-FAPI-04 has receptor specificity for malignant neoplasms with overexpression of the fibroblast activation protein and is used to visualize various types of neoplasms, in particular head and neck cancer, gastrointestinal tract, lung, breast cancer with a high contrast ratio of the tumor to the background, and may possibly become an alternative to 18F-FDG.OBJECTIVE: The results of the first experience of using PET/CT with 68Ga-FAPI-04 in Russia.MATERIALS AND METHODS: A comparative analysis of the results of 68Ga-FAPI-04 and 18F-FDG PET/CTs with an interval of 1–3 days was carried out in 13 patients (four women and nine men) with various oncological diseases, examined from February to December 2021 in Granov Russian Research Center of Radiology and Surgical Technologies.RESULTS: In all 13 patients, it was possible to identify both primary tumors and their metastases with different tracer uptake. 68Ga-FAPI PET/CT compared with 18F-FDG PET/CT revealed more metastatic foci (135 vs 127) predominantly in the liver, peritoneum, mesentery, omentum, and brain due to low background uptake in these organs. In our observation, foci of increased 68Ga-FAPI-04 uptake localized in non-enlarged retroperitoneal lymph nodes in two patients. Also, in two patients with bone metastases from bladder cancer and stomach cancer, one false positive and one false negative result was obtained with 68Ga-FAPI-04.DISCUSSION: The high uptake of 68Ga-FAPI-04 in the tumor makes it a promising tracer for many types of cancer, especially in cases, where conventional 18F-FDG PET/CT faces limitations due to its pharmacokinetics. At the same time, PET/CT with 68Ga-FAPI-04, aimed at visualizing the tumor microenvironment, may have a higher sensitivity in detecting small lesions due to the predominance of stroma in them. 68Ga-FAPI showed better results in detecting both lytic and osteoblastic bone metastases compared to 18F-FDG.CONCLUSION: 68Ga-FAPI is a promising tracer for molecular imaging of most malignant neoplasms and requires further study. 68Ga-FAPI-04 can become an addition or a full-fledged solution when other tracers have limitations.

  • Open Access

    Metabolic Tumor Volume for Patients with Lymphomas

    by Yu. N. Vinogradova, N. V. Ilyin, M. S. Tlostanova, A. A. Ivanova

    Visual analysis of positron emission tomography/computed tomography (PET/CT) scans and semiquantitative parameter of glucose’s standardized uptake value are used in PET/CT with18F-fluorodeoxyglucose (18F-FDG). Recently some volumetric parameters, which can evaluate metabolic tumor volume for patients with lymphomas and total lesion glycolysis in the tumor sites are established. In our study this problem was analyzed for different types of lymphomas considering clinical importance of these rates and their bond to known factors of international prognostic index.


  • Open Access

    Methodological Aspects of Measuring Metabolic Tumor Volume in Patients with Diffuse B-Cell Large Cell Lymphoma by PET/CT with 18F-FDG

    by Yu. N. Vinogradova, M. S. Tlostanova, A. A. Ivanova, A. Yu. Pakhomov, N. V. Ilyin

    Introduction: Metabolic Tumor Volume (MTV) and Total Tumor Lesion Glycolysis (TLG) are used in 18F-fluorodeoxyglucose Positron-Emission Tomography combined with Computed Tomography (18F-FDG PET/CT) as functional markers, indicating tracer uptake in whole tumor. MTV and TLG are not yet engaged in clinical practice, because volume measurement accuracy depends on the selected measurement method, and optimal MTV and TLG segmentation is not established.Purpose: Assessment of accuracy of metabolic tumor volume measurement ways, using 18F-FDG PET/CT in patients with Diffuse Large B-Cell Lymphoma (DLBCL).Material and methods: Baseline 18F-FDG PET/CT performed in 21 patients with DLBCL. Tumor Volume (TV), measured on contrast enhanced CT (CTTV), considered as reference. While measuring MTV, we aimed to achieve a 1:1 ratio between CTTV and MTV. If anatomical and metabolic tumor contours matched, MTV was considered true (MTVtrue). Overall MTV and TLG measurements are 254. Tumor contouring, using relative thresholds, was made around Standardized Uptake Value (SUVmax) of tracer in tumor and intact liver.Results: On CT, the size of the lesions varied from 24 to 241 mm, M = 103.4±62.3, Me = 93 (48.5–155.5). In 15 (71.4 %) foci, hypodense areas of necrosis were determined. PET imaging revealed high tracer uptake in all foci of varying degrees of intensity. SUVmax values in tumors ranged from 5.8 to 30.5, Me = 20.4 (17.3–23.2). No significant correlation was found between the size of the foci and SUVmax (ρ = 0.17, p = 0.4744). The best accuracy in measuring MTV was observed when several thresholds were applied: VOIPERCIST, VOI2.5, VOIauto-contour, as well as VOI10 %, VOI15 % and VOI20 %. The optimal absolute threshold values were SUV values in the range from 2 to 3, and relative values in the range from 10 % to 20 % of the SUVmax in the tumor. MTV underestimation was more often determined using relative cut-off indices in the range of25–50 % and SUV thresholds ≥ 5.3.Conclusion: The results obtained showed that the use of a single threshold value for MTV segmentation in patients with DLBCL is not advisable. The choice of the MTV measurement method should be carried out individually for each lesion, taking into account its shape, size and structure, as well as the intensity and uniformity of tracer uptake in the tumor and adjacent anatomical structures.